Title |
Acalabrutinib: First Global Approval
|
---|---|
Published in |
Drugs, December 2017
|
DOI | 10.1007/s40265-017-0852-8 |
Pubmed ID | |
Authors |
Anthony Markham, Sohita Dhillon |
Abstract |
Acerta Pharma is developing the Bruton's tyrosine kinase inhibitor acalabrutinib (Calquence®) for the treatment of various haematological and solid malignancies. The drug has received accelerated approval from the US FDA for the treatment of mantle cell lymphoma based on the results of a phase II study, and phase III trials in mantle cell lymphoma and chronic lymphocytic leukaemia are currently underway. This article summarizes the milestones in the development of acalabrutinib leading to this first approval for mantle cell lymphoma. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Egypt | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 43 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 8 | 19% |
Student > Bachelor | 5 | 12% |
Researcher | 4 | 9% |
Other | 3 | 7% |
Student > Master | 3 | 7% |
Other | 5 | 12% |
Unknown | 15 | 35% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 7 | 16% |
Pharmacology, Toxicology and Pharmaceutical Science | 7 | 16% |
Chemistry | 6 | 14% |
Medicine and Dentistry | 3 | 7% |
Arts and Humanities | 1 | 2% |
Other | 4 | 9% |
Unknown | 15 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 December 2017.
All research outputs
#18,578,649
of 23,011,300 outputs
Outputs from Drugs
#3,019
of 3,287 outputs
Outputs of similar age
#327,145
of 439,586 outputs
Outputs of similar age from Drugs
#19
of 20 outputs
Altmetric has tracked 23,011,300 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,287 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one is in the 3rd percentile – i.e., 3% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 439,586 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.